Related Experiment Video
Updated: May 10, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
Progress in HIV-1 vaccine development
Barton F Haynes1, M Juliana McElrath
1Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA. hayne002@mc.duke.edu
Purpose Of Review:
In this review, examples of recent progress in HIV-1 vaccine research are discussed.
Recent Findings:
New insights from the immune correlates analyses of the RV144 efficacy trial have accelerated vaccine development with leads to follow in nonhuman primate studies and improved vaccine designs. Several new vaccine vector approaches offer promise in the exquisite control of acute infection and in improving the breadth of T-cell responses. New targets of broadly neutralizing antibodies (BnAbs) have been elucidated, and improved understanding of how the human host controls BnAb development have emerged from BnAb knock-in mice and from analyses of BnAb maturation and virus evolution in individuals followed from the time of HIV-1 transmission to BnAb induction.
Summary:
Based on these observations, it is clear that the development of a successful HIV-1 vaccine will require new vaccine approaches and iterative testing of immunogens in well designed animal and human trials.
More Related Videos
Related Concept Videos
Vaccine Production
Preclinical Development: Overview
Clinical Trials: Overview

